Quest Pharmatech (QPT.V) Stock Price

Quest Pharmatech Inc., trading under the ticker QPT.V, is a biotechnology company headquartered in Edmonton, Alberta, Canada. The company was founded on July 23, 1997, and operates within the health care sector, specifically in biotechnology. Its primary focus is the development and commercialization of antibody-based immunotherapeutic products for cancer treatment. Quest Pharmatech is developing a proprietary diagnostic agent called MAb-AR9.6, which targets MUC16, for cancer detection. This technology is licensed from the University of Nebraska Medical Centre and is currently in late preclinical development. The company holds a 42.5% ownership interest in OncoQuest Inc., a biotechnology firm specializing in combinatorial immunotherapy products for cancer treatment. OncoQuest's technology platform includes tumor antigen-specific monoclonal antibodies targeting various cancer markers such as CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72. Additionally, Quest Pharmatech has a 23% ownership stake in OncoVent, a company focused on developing antibody-based immunotherapeutic products for cancer in the Greater China region. The company's website is http://www.questpharmatech.com/, and it operates under the ISIN CA74836M1068. Quest Pharmatech aims to improve the quality of life for cancer patients through its innovative therapeutic approaches.